PuSH - Publikationsserver des Helmholtz Zentrums München

Greif, P.A. ; Dufour, A.* ; Konstandin, N.P. ; Ksienzyk, B.* ; Zellmeier, E. ; Tizazu, B. ; Sturm, J. ; Benthaus, T.* ; Herold, T.* ; Yaghmaie, M. ; Dorge, P.* ; Hopfner, K.P.* ; Hauser, A.* ; Graf, A.* ; Krebs, S.* ; Blum, H.* ; Kakadia, P.M.* ; Schneider, S.* ; Hoster, E.* ; Schneider, F.* ; Stanulla, M.* ; Braess, J.* ; Sauerland, M.C.* ; Berdel, W.E.* ; Büchner, T.* ; Woermann, B.J.* ; Hiddemann, W. ; Spiekermann, K. ; Bohlander, S.K.

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.

Blood 120, 395-403 (2012)
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Cytogenetically normal acute myeloid leukemia (CN-AML) with biallelic CEBPA gene mutations (biCEPBA) represents a distinct disease entity with a favorable clinical outcome. So far, it is not known whether other genetic alterations cooperate with biCEBPA mutations during leukemogenesis. To identify additional mutations, we performed whole exome sequencing of 5 biCEBPA patients and detected somatic GATA2 zinc finger 1 (ZF1) mutations in 2 of 5 cases. Both GATA2 and CEBPA are transcription factors crucial for hematopoietic development. Inherited or acquired mutations in both genes have been associated with leukemogenesis. Further mutational screening detected novel GATA2 ZF1 mutations in 13 of 33 biCEBPA-positive CN-AML patients (13/33, 39.4%). No GATA2 mutations were found in 38 CN-AML patients with a monoallelic CEBPA mutation and in 89 CN-AML patients with wild-type CEBPA status. The presence of additional GATA2 mutations (n = 10) did not significantly influence the clinical outcome of 26 biCEBPA-positive patients. In reporter gene assays, all tested GATA2 ZF1 mutants showed reduced capacity to enhance CEBPA-mediated activation of transcription, suggesting that the GATA2 ZF1 mutations may collaborate with biCEPBA mutations to deregulate target genes during malignant transformation. We thus provide evidence for a genetically distinct subgroup of CN-AML. The German AML cooperative group trials 1999 and 2008 are registered with the identifiers NCT00266136 and NCT01382147 at www.clinicaltrials.gov. (Blood. 2012; 120(2): 395-403)
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Transcription Factor GATA-2; High-Dose Cytarabine; Dnmt3a Mutations; Somatic Mutations; Lymphoblastic-Leukemia; Initiating Cells; DNA-Binding; Expression; Distinct; Differentiation
ISSN (print) / ISBN 0006-4971
e-ISSN 1528-0020
Zeitschrift Blood
Quellenangaben Band: 120, Heft: 2, Seiten: 395-403 Artikelnummer: , Supplement: ,
Verlag American Society of Hematology
Begutachtungsstatus Peer reviewed